Ensign Peak Advisors Inc Acquires 1,975 Shares of Guardant Health, Inc. $GH

Ensign Peak Advisors Inc grew its holdings in Guardant Health, Inc. (NASDAQ:GH) by 4.8% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 43,425 shares of the company’s stock after buying an additional 1,975 shares during the quarter. Ensign Peak Advisors Inc’s holdings in Guardant Health were worth $2,260,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Intech Investment Management LLC increased its stake in shares of Guardant Health by 37.3% in the 1st quarter. Intech Investment Management LLC now owns 60,187 shares of the company’s stock valued at $2,564,000 after buying an additional 16,363 shares during the period. Yorktown Management & Research Co Inc bought a new stake in shares of Guardant Health in the 2nd quarter valued at about $289,000. Osterweis Capital Management Inc. bought a new stake in Guardant Health in the first quarter valued at approximately $12,634,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Guardant Health by 6.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,236 shares of the company’s stock valued at $3,035,000 after buying an additional 4,056 shares in the last quarter. Finally, Strs Ohio acquired a new stake in shares of Guardant Health during the first quarter worth about $809,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on GH. Weiss Ratings restated a “sell (d-)” rating on shares of Guardant Health in a report on Wednesday, October 8th. TD Cowen upped their price objective on Guardant Health from $63.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, September 25th. Wolfe Research raised shares of Guardant Health from a “peer perform” rating to an “outperform” rating and set a $75.00 target price on the stock in a report on Thursday, September 25th. Leerink Partners raised their price target on Guardant Health from $70.00 to $75.00 and gave the company an “outperform” rating in a report on Thursday, September 25th. Finally, Barclays boosted their price objective on Guardant Health from $70.00 to $85.00 and gave the stock an “overweight” rating in a report on Thursday, October 30th. Twenty-three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Guardant Health presently has an average rating of “Moderate Buy” and an average target price of $77.14.

Guardant Health Trading Down 0.9%

Shares of GH opened at $107.79 on Thursday. Guardant Health, Inc. has a 12 month low of $29.91 and a 12 month high of $112.43. The firm’s 50 day moving average is $78.15 and its 200-day moving average is $60.06. The stock has a market capitalization of $13.59 billion, a PE ratio of -33.58 and a beta of 1.56.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.09. During the same period in the prior year, the firm earned ($0.88) earnings per share. The firm’s revenue was up 38.5% on a year-over-year basis. Guardant Health has set its FY 2025 guidance at EPS. Equities research analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Insider Transactions at Guardant Health

In other news, insider John G. Saia sold 8,996 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $96.25, for a total transaction of $865,865.00. Following the sale, the insider directly owned 43,172 shares of the company’s stock, valued at approximately $4,155,305. This represents a 17.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Medina Manuel Hidalgo sold 1,500 shares of the firm’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $95.19, for a total value of $142,785.00. Following the completion of the transaction, the director owned 815 shares in the company, valued at $77,579.85. The trade was a 64.79% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 313,161 shares of company stock valued at $18,996,062. 6.10% of the stock is owned by corporate insiders.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.